Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teglitide vs sufentanil for postoperative analgesia after thoracoscopic lobectomy
ChiCTR2600121522Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sufentanil (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Pain intensity within 48 hours after surgery. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
sufentanil
Beyond the preview
Go deeper on ChiCTR2600121522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121522.